SCHEMBL4055334

SCHEMBL4055334

Cc1ccc(CCc2nc3ncc(-c4ccccc4)cc3[nH]2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 3/20 0.59
NOS1 P29475 3/20 0.59
NOS2 P35228 3/20 0.59
NTRK1 P04629 3/20 0.44
RAB9A P51151 3/20 0.43
NPC1 O15118 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
GFER P55789 1/20 0.43
DAGLA Q9Y4D2 1/20 0.43
PDE10A Q9Y233 1/20 0.42
BRS3 P32247 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
USP30 Q70CQ3 3/20 0.40
POLB P06746 1/20 0.40
NTRK2 Q16620 1/20 0.38
PLK4 O00444 1/20 0.38
CHEK1 O14757 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058698 0.91 NOS3 (0.62) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4057994 0.88 NOS3 (0.56) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4057459 0.88 NOS3 (0.56) NOS3NOS1NOS2NTRK1RAB9A
SCHEMBL4053930 0.88 NOS3 (0.56) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4053669 0.87 NOS1 (0.71) NOS3NOS1NOS2NTRK1BRS3
SCHEMBL4057686 0.87 NOS3 (0.56) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4052894 0.86 NOS1 (0.61) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4050811 0.84 NOS3 (0.53) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4059226 0.84 NOS3 (0.53) NOS3NOS1NOS2NTRK1RAB9A
SCHEMBL4054242 0.84 NOS3 (0.59) NOS3NOS1NOS2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS3 907/4885NOS1 879/4885NOS2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.